Biochemistry News and Research

RSS

Interdisciplinary research leads to first known use of smart nanofilm on living tissue

Louisiana Tech students Mridhula Thangaraj and Chris Monceaux will participate in a symposium on 'Regenerative Medicine - Wound Healing' at the 2010 Experimental Biology meeting, April 24-28 at the Anaheim Convention Center.

23 Apr 2010

BUSM professor receives Individual Biomedical Research Award

Richard Goldstein, PhD, a professor of pediatrics, division of pediatric infectious diseases, at Boston University School of Medicine, has been awarded an Individual Biomedical Research Award by The Hartwell Foundation and will receive $300,000 over three years as a Hartwell Investigator for his project titled, "A Vaccine Against Streptococcus Pneumoniae Based on Bacterial Surface Proteins Phylogenically Certified as Highly Conserved."

23 Apr 2010

Aragon Pharmaceuticals raises $22M through Series B financing

Aragon Pharmaceuticals Inc. today announced that it has secured $22 million in Series B financing.

23 Apr 2010

Molecular mechanisms of hypertension, its diagnosis and treatment to be focused at ASBMB's symposium

About 1 billion people around the world suffer from hypertension. The molecular mechanisms of this disease, its diagnosis and treatment will be the focus of a lecture series at the American Society for Biochemistry and Molecular Biology's annual meeting in Anaheim, Calif. The talks will take place from Monday, May 26 through Wednesday, April 28 in room 304C of the Anaheim Convention Center.

23 Apr 2010

Removable methyl groups on specific genes of autistic individuals that led to gene silencing identified

A new study by researchers at The George Washington University School of Medicine and Health Sciences' Department of Biochemistry and Molecular Biology raises hope that autism may be more easily diagnosed and that its effects may be more reversible than previously thought.

22 Apr 2010

Alnylam Pharmaceuticals presents new data on ALN-TTR01 RNAi therapeutic at amyloidosis symposium

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, presented new pre-clinical data from its ALN-TTR program at the XII International Symposium on Amyloidosis in Rome on April 18 - 21, 2010. ALN-TTR01 is a systemically delivered RNAi therapeutic being developed for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR), including familial amyloidotic polyneuropathy (FAP) and familial amyloidotic cardiomyopathy (FAC).

22 Apr 2010

Agios Pharmaceuticals presents data on cancer-associated IDH1 mutations at 101st AACR meeting

Agios Pharmaceuticals, a biopharmaceutical company focused on discovering and developing novel drugs in the field of cancer metabolism, today announced multiple presentations at the American Association for Cancer Research (AACR) 101st Annual Meeting that highlight cancer metabolism as an approach to identify new ways to treat cancer, opening the potential for a new class of cancer drugs targeting metabolic enzymes.

22 Apr 2010

Study identifies the source of inherent noise in HIV gene expression

New research identifies a molecular mechanism that the human immunodeficiency virus (HIV) appears to utilize for generating random fluctuations called "noise" in its gene expression.

21 Apr 2010

Interim results from QLT's Phase 1b study of QLT091001 for Leber congenital amaurosis

QLT Inc. today announced interim results from the first 3 subjects enrolled in a Phase 1b clinical proof-of-concept study of QLT091001 in the treatment of Leber congenital amaurosis (LCA), an inherited progressive retinal degenerative disease that leads to retinal dysfunction and significant visual impairment beginning at birth. QLT091001 is an orally administered synthetic retinoid replacement for 11-cis-retinal, which is a key biochemical component of visual function.

20 Apr 2010

Potential mate's signal activates molecular switch

A mystery about the mechanism behind sexual mate selection has been resolved. According to a new study published in the journal Nature, Universit- de Montr-al researchers have discovered a molecular switch that becomes activated in response to a potential mate's signal. Simply put, an organism knows that a potential mate is close-by and healthy enough to mate.

19 Apr 2010

New insights into yeast cells may help identify cancer cells and stem cells development: Study

Yeast cells decide whether to have sex with each other within two minutes of meeting, according to new research published today in Nature. One of the authors of the study, from Imperial College London, says the new insights into how yeast cells decide to mate could be helpful for researchers looking at how cancer cells and stem cells develop.

19 Apr 2010

Enhancing drug residence time may help develop better diagnostic, therapeutic agents

Research conducted at the Stony Brook University Institute for Chemical Biology & Drug Discovery that enhances the time a drug remains bound to its target, or residence time, may prove to be an important step in developing better diagnostic and therapeutic agents based partly on longer drug residence time.

17 Apr 2010

NSF Faculty Early Career Development Award for Zhihao Zhuang

Zhihao Zhuang, assistant professor in the Department of Chemistry and Biochemistry at the University of Delaware, has won the National Science Foundation Faculty Early Career Development Award.

17 Apr 2010

Marker found in iPS cells correlates with levels of pluripotency: Researchers

Researchers in China are reporting that they have found a way to determine which somatic cells -- or differentiated body cells -- that have been reprogrammed into a primordial, embryonic-like state are the most viable for therapeutic applications.

17 Apr 2010

Study links cancer growth to sugar-based modification found naturally in the body

Researchers at Drexel University College of Medicine have discovered that a certain type of sugar found naturally in the body is elevated in breast cancer cells and is critical for cancer growth and movement. When researchers reduced and normalized the levels of this sugar, they were able to slow the growth of the cancer cells and block invasion. The findings, published in the March 1 issue of Oncogene, represent a potential new therapeutic target for treating aggressive forms of breast cancer.

15 Apr 2010

Celgene, Agios Pharmaceuticals form global strategic collaboration on targeting cancer metabolism

Celgene Corporation and Agios Pharmaceuticals Inc., a privately-held biotechnology company, today announced the formation of a global strategic collaboration focused on targeting cancer metabolism. The goal of the collaboration is to discover, develop, and deliver novel disease-altering therapies in oncology based on the transformational science of Agios' innovative cancer metabolism research platform. This platform is based on the concept that targeting key metabolic enzymes unique to rapidly proliferating cancer cells can "starve" the cancer.

15 Apr 2010

Scientists uncover new genes responsible for cancer, deafness

From deep within the genomes of organisms as diverse as plants, worms and yeast, scientists have uncovered new genes responsible for causing human diseases such as cancer and deafness.

15 Apr 2010

Researchers invent zinc-stapled insulin to reduce insulin-related cancer risk

For millions of Americans with Type-2 diabetes and inject insulin to control diabetes (with onset typically in adulthood) the associated risk of cancer is of increasing concern. Studies have demonstrated that obesity and excess insulin - whether naturally produced by the body or injected in synthetic form - are associated with an increased incidence of some common cancers.

13 Apr 2010

Stress hormones may suppress tumor growth: Study

Chronic stress triggers a chain of molecular events that protects breakaway ovarian cancer cells from destruction, a team of researchers led by scientists at The University of Texas M. D. Anderson Cancer Center reports April 12 in the early online publication of the Journal of Clinical Investigation.

13 Apr 2010

Gilead Sciences doses first patient in Quad Phase III clinical program

Gilead Sciences, Inc. today announced that it has dosed the first patient in the Phase III clinical program evaluating its investigational fixed-dose, single-tablet "Quad" regimen of elvitegravir, cobicistat (formerly GS 9350), emtricitabine and tenofovir disoproxil fumarate.

13 Apr 2010

Biochemistry News and Research

Interdisciplinary research leads to first known use of smart nanofilm on living tissue

BUSM professor receives Individual Biomedical Research Award

Aragon Pharmaceuticals raises $22M through Series B financing

Molecular mechanisms of hypertension, its diagnosis and treatment to be focused at ASBMB's symposium

Removable methyl groups on specific genes of autistic individuals that led to gene silencing identified

Alnylam Pharmaceuticals presents new data on ALN-TTR01 RNAi therapeutic at amyloidosis symposium

Agios Pharmaceuticals presents data on cancer-associated IDH1 mutations at 101st AACR meeting

Study identifies the source of inherent noise in HIV gene expression

Interim results from QLT's Phase 1b study of QLT091001 for Leber congenital amaurosis

Potential mate's signal activates molecular switch

New insights into yeast cells may help identify cancer cells and stem cells development: Study

Enhancing drug residence time may help develop better diagnostic, therapeutic agents

NSF Faculty Early Career Development Award for Zhihao Zhuang

Marker found in iPS cells correlates with levels of pluripotency: Researchers

Study links cancer growth to sugar-based modification found naturally in the body

Celgene, Agios Pharmaceuticals form global strategic collaboration on targeting cancer metabolism

Scientists uncover new genes responsible for cancer, deafness

Researchers invent zinc-stapled insulin to reduce insulin-related cancer risk

Stress hormones may suppress tumor growth: Study

Gilead Sciences doses first patient in Quad Phase III clinical program

Measuring Drug-Target Residence Times with Biochemical Assays eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery